Your browser doesn't support javascript.
loading
Adverse drug reactions and drug interactions in the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19).
Marins, Tatiana A; Marra, Alexandre R; Edmond, Michael B; Colombo, Ligia Regina Prystaj; Vieira, Sthephanie Favalli; de Oliveira Xavier, Fernanda; Chauvin, Alessandra Gomes; Pinho, João Renato Rebello; de Almeida, Silvana M; Junior, Marcelino Souza Durão.
Afiliación
  • Marins TA; Department of Clinical Pharmacy, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Marra AR; Instituto Israelita de Ensino e Pesquisa Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Edmond MB; Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States.
  • Colombo LRP; West Virginia University School of Medicine, Morgantown, West Virginia, United States.
  • Vieira SF; Department of Clinical Pharmacy, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • de Oliveira Xavier F; Department of Clinical Pharmacy, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Chauvin AG; Department of Clinical Pharmacy, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Pinho JRR; Department of Clinical Pharmacy, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • de Almeida SM; Special Techniques Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Junior MSD; Department of Clinical Pharmacy, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Antimicrob Steward Healthc Epidemiol ; 1(1): e38, 2021.
Article en En | MEDLINE | ID: mdl-36168493
Objectives: To identify drugs that were administered off label to hospitalized patients with suspected coronavirus disease 2019 (COVID-19) and to identify adverse drug reactions (ADRs) and drug-drug interactions associated with these therapies. Methods: This case-control study was conducted in a Brazilian hospital from March to April 2020 among patients with suspected COVID-19, comparing those with positive severe acute respiratory coronavirus virus 2 (SARS-CoV-2) reverse-transcriptase polymerase chain reaction (RT-PCR) results and those with negative results. Results: The most commonly used medications in both groups were azithromycin and hydroxychloroquine. There was a significantly higher prevalence of reactions among patients with positive RT-PCR for SARS-CoV-2 (48.5% vs 28.8%; P = .008) in the propensity score-matched cohort, and the most commonly reported ADRs among these patients were diarrhea (43.8%), elevated liver enzymes (31.3%), and nausea and vomiting (29.7%). Conclusions: Our data demonstrate that ADRs and drug-drug interactions are common with off-label treatments for COVID-19.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Antimicrob Steward Healthc Epidemiol Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Antimicrob Steward Healthc Epidemiol Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido